CSIMarket Company Name, Ticker, Suppliers, else..
 
Tvardi Therapeutics Inc   (NASDAQ: TVRD)
 
Price: $1.9050 $-0.04 -1.804%
Day's High: $1.940000057220459 Week Perf: 1.33 %
Day's Low: $ 1.87 30 Day Perf: 8.24 %
Volume (M): 68,869 52 Wk High: $ 43.65
Volume (M$): $ 0 52 Wk Avg: $6.64
Open: $1.92 52 Wk Low: $1.50



 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 9
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage biopharmaceutical firm developing oral small molecule therapies that inhibit the transcription factor STAT3 to treat inflammatory and proliferative diseases. Its pipeline includes two STAT3 inhibitors, TTI-101 and TTI-109, targeting conditions such as hepatocellular carcinoma and idiopathic pulmonary fibrosis. The company has ongoing clinical trials and has received FDA designations related to these therapies. Its approach focuses on modulating disease pathways associated with STAT3 while preserving essential cellular functions.


   Company Address: 3 Sugar Creek Ctr. Blvd. Sugar Land 77478 TX
   Company Phone Number: 489-8654   Stock Exchange / Ticker: NASDAQ TVRD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AKBA        8.47% 
ATXI        16.15% 
BFRG        0.21% 
BTAI   -73.62%    
JAGX   -45.38%    
VTGN   -0.71%    
• View Complete Report
   



Business Update

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Published Mon, Oct 13 2025 8:18 PM UTC

Novel Insights into Idiopathic Pulmonary Fibrosis: Tvardi Therapeutics Advances with Promising Phase 2 Trial Results for TTI-101In the ever-evolving landscape of therapeutics for fibrotic diseases, Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is making significant strides in addressing the challenges posed by idiopathic pulmonary fibrosis (IPF). The Houston-based clinical-s...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.13
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.39
Working Capital Ratio 3.61
Leverage Ratio (MRQ) 1.09
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.94 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.29 $
Book Value 0.89 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,561,333
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.